<DOC>
	<DOCNO>NCT00683917</DOCNO>
	<brief_summary>PK 25 mg 50 mg Proellex速 administer daily ( QD ) 4-month period .</brief_summary>
	<brief_title>Pharmacokinetics , Safety Efficacy Study Proellex Pre-menopausal Women With Symptomatic Uterine Fibroids</brief_title>
	<detailed_description>The primary objective evaluate pharmacokinetics ( PK ) 25 mg 50 mg Proellex速 administer daily ( QD ) 4-month period .</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Female subject age 18 45 year body mass index ( BMI ) 18 35 mg/kg2 inclusive Surgical intervention uterine fibroid ( e.g. , hysterectomy , myomectomy , uterine arterial embolization ) must plan anticipate study Subject must follow uterine fibroidassociated symptom : history excessive menstrual bleeding Regular steady menstrual cycle last 24 36 day Willing comply study procedure include endometrial biopsy PK blood draw visit include followup visit Subject must agree use medically acceptable effective nonhormonal , double barrier birth control method throughout study 30 day follow end study discontinuation study drug Documented endometriosis active pelvic inflammatory disease History alcohol and/or drug abuse Any history diagnosis gynecological cancer cervical dysplasia Use IUD Use prohibit concomitant medication : Use DepoProvera must cease 10 month prior first dose study drug Use GnRH agonist ( e.g. , Lupron速 ) must cease 4 month prior first dose study drug Lupton速 Depot 8 month prior first visit Known active infection HIV ; Hepatitis A , B C ; gonorrhea ; chlamydia</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Uterine fibroid</keyword>
	<keyword>Fibroids</keyword>
</DOC>